<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271085</url>
  </required_header>
  <id_info>
    <org_study_id>H2020-825731</org_study_id>
    <nct_id>NCT04271085</nct_id>
  </id_info>
  <brief_title>Living Well, Dying Well. A Research Programme to Support Living Until the End</brief_title>
  <acronym>iLIVE</acronym>
  <official_title>Living Well, Dying Well. A Research Programme to Support Living Until the End (iLIVE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum der Universität Köln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University Clinic of Pulmonary and Allergic Diseases Golnik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cudeca Hospice Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse-Bergen HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Landspitali University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pallium Latinoamérica N.G.O</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Humanistic Studies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arohanui Hospice Service Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Vincent's Hospital Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The iLIVE project involves a cohort study in which patients with an estimated life expectancy&#xD;
      of six months or less are followed until they die. In total, the investigators will include&#xD;
      2200 patients in 11 countries, i.e. 200 per country. The primary outcome for the cohort study&#xD;
      is a descriptive assessment of the concerns, expectations and preferences around dying and&#xD;
      end-of-life care of patients and their relatives, in different settings and cultures..&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: In the EU about 4 million people yearly die from a chronic illness. Many of these&#xD;
      people die in pain or distress. Care for dying patients and their close relatives is often&#xD;
      suboptimal.&#xD;
&#xD;
      Objective: To contribute to high-quality personalized care at the end of life by:&#xD;
&#xD;
        1. Providing in-depth understanding of the concerns, expectations and preferences of&#xD;
           patients in the last phase of life and their relatives&#xD;
&#xD;
        2. Understanding the cultural, gender, age, healthcare -related and socio-economic variance&#xD;
           in these concerns expectations and preferences Study design: The iLIVE project involves&#xD;
           a cohort study in which patients with an estimated life expectancy of six months or less&#xD;
           are followed until they die. In total, the investigators will include 2200 patients in&#xD;
           11 countries, i.e. 200 per country. Participants are requested to also involve a close&#xD;
           relative. Both patients and relatives are asked to fill in a questionnaire, at baseline&#xD;
           and after four weeks. If patients die during the study, the relative is asked to fill in&#xD;
           a post-bereavement questionnaire. Medical files are studied to assess health care use in&#xD;
           the last days of life.&#xD;
&#xD;
      Main study endpoints: The primary outcome for the cohort study is a descriptive assessment of&#xD;
      patients' concerns, expectations and preferences around dying and end-of-life care, at&#xD;
      baseline and after one month of follow-up.&#xD;
&#xD;
      Potential risks and benefits associated with participation: The study population concerns&#xD;
      vulnerable people who may experience fluctuating symptoms and levels of suffering across&#xD;
      their disease trajectory. The investigators acknowledge the risk of overburdening or&#xD;
      stigmatizing participants. If patients feel burdened by participating in the study, they are&#xD;
      encouraged to indicate that. The investigators will develop a protocol for researchers and&#xD;
      interviewers to address such situations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concerns, expectations and preferences around dying and end-of-life care (descriptive assessment of prevalence)</measure>
    <time_frame>Baseline</time_frame>
    <description>Self developed questions, adapted from the Serious Illness Conversation Guide and the AEOLI questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concerns, expectations and preferences around dying and end-of-life care (descriptive assessment of prevalence)</measure>
    <time_frame>One month of follow-up</time_frame>
    <description>Self developed questions, which were inspired by the Serious Illness Conversation Guide and the AEOLI questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Edmonton Symptom Assessment Scale (range 0-10, with higher score meaning worse outcome)</measure>
    <time_frame>At baseline and after one month of follow-up</time_frame>
    <description>Symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organisation for Research and Treatment of Cancer Quality of Life C15-Palliative Care questionnaire, quality of life item (range 1-7, with higher score indicating better outcome)</measure>
    <time_frame>At baseline and after one month of follow-up</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol-5d questionnaire (range 1-5 per item, with higher score indicating worse outcome)</measure>
    <time_frame>At baseline and after one month of follow-up</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICECAP Supportive Care Measure (range 1-4 per item, with higher score indicating worse outcome)</measure>
    <time_frame>At baseline and after one month of follow-up</time_frame>
    <description>Experience of support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of medical interventions (hospitalisation, medication, surgery, other interventions)</measure>
    <time_frame>One week</time_frame>
    <description>Retrospective assessment for patients who die during follow-up of medical interventions in the last week of patients' life, using a self-developed checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bereaved relatives' experiences</measure>
    <time_frame>8-10 weeks post-bereavement</time_frame>
    <description>International Care of the dying questionnaire (descriptive), Hogan Grief Reaction Checklist (despair (13 items) and personal growth (12 items) scales, range 1-5 per item)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Terminal Care</condition>
  <arm_group>
    <arm_group_label>Patients in the last phase of life</arm_group_label>
    <description>Patients in the last phase of life and their families</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>No intervention involved</description>
    <arm_group_label>Patients in the last phase of life</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All competent adult patients with an estimated life expectancy of six months or less are&#xD;
        eligible, regardless of their diagnosis, gender or age, or place of residence, and their&#xD;
        relatives&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria patients:&#xD;
&#xD;
          -  The patient is aware that recovering from his/her disease is unlikely, to be assessed&#xD;
             by the attending physician&#xD;
&#xD;
          -  The attending physician would not be surprised if the patient were to die within 6&#xD;
             months&#xD;
&#xD;
          -  If the physician is uncertain about the surprise question, the patient is eligible if&#xD;
             presenting with at least one SPICT indicator:&#xD;
&#xD;
        General SPICT indicators:&#xD;
&#xD;
          -  Unplanned hospital admission&#xD;
&#xD;
          -  Performance status is poor or deteriorating, with limited reversibility (eg stays in&#xD;
             bed or in a chair for more than half the day)&#xD;
&#xD;
          -  Depends on others for care due to increasing physical and/or mental health problems;&#xD;
             person's carer needs more help and support&#xD;
&#xD;
          -  Progressive weight loss; remains underweight; low muscle mass&#xD;
&#xD;
          -  Persistent symptoms despite optimal treatment of underlying condition(s)&#xD;
&#xD;
          -  Person (or family) asks for palliative care; chooses to reduce, stop or not have&#xD;
             treatment; or wishes to focus on quality of life&#xD;
&#xD;
        Disease-specific SPICT indicators:&#xD;
&#xD;
        Cancer:&#xD;
&#xD;
          -  Functional ability deteriorating due to progressive cancer&#xD;
&#xD;
          -  Too frail for cancer treatment or treatment is for symptom control&#xD;
&#xD;
        Neurological disease:&#xD;
&#xD;
          -  Progressive deterioration in physical and/or cognitive function despite optimal&#xD;
             therapy&#xD;
&#xD;
          -  Speech problems with increasing difficulty communicating and/or progressive difficulty&#xD;
             with swallowing&#xD;
&#xD;
          -  Recurrent aspiration pneumonia; breathless or respiratory failure&#xD;
&#xD;
          -  Persistent paralysis after stroke with significant loss of function and ongoing&#xD;
             disability&#xD;
&#xD;
        Heart/vascular disease:&#xD;
&#xD;
          -  Heart failure or extensive, untreatable coronary artery disease; with breathlessness&#xD;
             or chest pain at rest or on minimal effort&#xD;
&#xD;
          -  Severe, inoperable peripheral vascular disease&#xD;
&#xD;
        Respiratory disease:&#xD;
&#xD;
          -  Severe, chronic lung disease; with breathlessness at rest or on minimal effort between&#xD;
             exacerbations&#xD;
&#xD;
          -  Persistent hypoxia needing long term oxygen therapy&#xD;
&#xD;
          -  Has needed ventilation for respiratory failure or ventilation is contraindicated&#xD;
&#xD;
        Kidney disease:&#xD;
&#xD;
          -  Stage 4 or 5 chronic kidney disease (eGFR &lt; 30ml/min) with deteriorating health&#xD;
&#xD;
          -  Kidney failure complicating other life limiting conditions or treatments&#xD;
&#xD;
          -  Stopping or not starting dialysis&#xD;
&#xD;
        Liver disease:&#xD;
&#xD;
          -  Cirrhosis with one or more complications in the past year: diuretic resistant ascites;&#xD;
             hepatic encephalopathy; hepatorenal syndrome; bacterial peritonitis; or recurrent&#xD;
             variceal bleeds&#xD;
&#xD;
          -  Liver transplant is not possible&#xD;
&#xD;
        Dementia/ frailty:&#xD;
&#xD;
          -  Unable to dress, walk or eat without help&#xD;
&#xD;
          -  Eating and drinking less, difficulty with swallowing&#xD;
&#xD;
          -  Urinary and faecal incontinence&#xD;
&#xD;
          -  Not able to communicate by speaking; little social interaction&#xD;
&#xD;
          -  Frequent falls; fractured femur&#xD;
&#xD;
          -  Recurrent febrile episodes or infections, aspiration pneumonia&#xD;
&#xD;
        Other conditions:&#xD;
&#xD;
        o Deteriorating and at risk of dying with other conditions or complications that are not&#xD;
        reversible; any treatment available will have a poor outcome&#xD;
&#xD;
        Exclusion Criteria patients:&#xD;
&#xD;
          -  The patient is incapable of filling in a questionnaire in the country's main language&#xD;
             or in English (patients may be supported by relatives when filling in the&#xD;
             questionnaire)&#xD;
&#xD;
          -  The patient is incapable of providing informed consent to participate in the study, to&#xD;
             be assessed by the attending physician&#xD;
&#xD;
        Inclusion Criteria relatives:&#xD;
&#xD;
          -  Family, friend or other close relative of the patient&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  The relative is aware that it is unlikely that that patient will recover from his/her&#xD;
             disease&#xD;
&#xD;
        Exclusion Criteria relatives:&#xD;
&#xD;
          -  The relative is incapable of filling in a questionnaire in the country's main language&#xD;
             or in English&#xD;
&#xD;
          -  The relative is incapable of providing informed consent to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnes van der Heide, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agnes van der Heide, PhD</last_name>
    <phone>+310107043719</phone>
    <phone_ext>+310107043719</phone_ext>
    <email>a.vanderheide@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pallium Latinoamérica</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilma Tripodoro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Voltz, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landspitali National University Hospital of Iceland</name>
      <address>
        <city>Reykjavík</city>
        <country>Iceland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valgerður Sigurðardóttir, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agnes van der Heide</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes van der Heide, PhD</last_name>
      <phone>+310107043719</phone>
      <phone_ext>+310107043719</phone_ext>
      <email>a.vanderheide@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arohanui Hospice Service</name>
      <address>
        <city>Palmerston North</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Allan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagny Faksvåg Haugen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic for Respiratory and Allergic Diseases Golnik</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urska Lunder, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Cuidados Paliativos Cudeca</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisa Martín-Roselló, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carl Johan Fürst, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steffen Eychmüller, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Liverpool</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Ellershaw, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Germany</country>
    <country>Iceland</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 27, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Agnes van der Heide</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Patients in the last phase of life</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

